异构性固化瘤苗临床应用观察  

Study of the clinical application of heteroid solidified tumor vaccine.

作　　者：周魁宏 黄皎林 钱叶长 程高[1,2,3] 

机构地区：[1]上海空军455医院 [2]重庆热疗肿瘤研究所 [3]铜陵市人民医院

出　　处：《中国肿瘤临床与康复》1999年第3期1-5,共5页Chinese Journal of Clinical Oncology and Rehabilitation

摘　　要：目的为实现特异性细胞免疫抗癌治疗。自体固化瘤苗研究者，突破性将异体癌研制成功的异构性固化瘤苗，进行临床应用观察。方法瘤苗先经动物实验，药理和毒理试验，证明其制剂无毒付作用，和抗癌有效性后。我们院所合作，对１５６例多类（肺癌５３例，肝癌２２例，食道癌１４例，胃癌２５例，直肠癌１２例，乳腺癌３０例）癌，经手术切除主瘤但病理证实已有转移的中晚期癌症病人（自愿者）进行临床应用观察。结果获近期（三个月）临床抗癌有效率７５％（１１７／１５６），远期（三年）疗效６６．６％（１０３／１５６）。发现Ｔ淋巴细胞（ＣＴＬ）攻入癌细胞中，而使癌细胞凋亡。结论异构性固化瘤苗，能激活机体抗癌三分子复体免疫（ＳＴＶ－ＭＨＣ－ＴＣＲ）机制。实现了在人体内（ｉｎｖｉｒｏ途径）使癌细胞呈治疗性凋亡的特异性细胞免疫抗癌效果。Objective To Study an clinical application of heteroid solidified tumor vaccine.Methods The heteroid solidified tumor vaccine was confirmed to be non-toxic and efficient in cancer therapy with the animal experiments,this heteroid solidified tumor vaccine was used clinically.Many kinds of advanced cancers (volunteers,including 53 cases with lung cancer,22 cases with liver cancer,30 cases with breast cancer.14 cases with esophageal cancer.12 Cases with rectal cancer.25 cases with stomach cancer) were treated with the tumor vaccine.Results The result showed that the immediate rate of officient therapy was 75% (117/156 cases) and the 3-years survival rate was 66.6% (103/156).The cancer cells were invaded by T-cells to result in apoptosis of The cancer cells by pathological examination.Conclusions The heteroid solidified tumor vaccine is a valuable agent in canaer therapy.The mechanism of anti-cancer of the heteroid solidified tumor vaccine mybe throagh the pathway of STV-MHC-TCR.

关 键 词：特异性免疫 异构性 固化瘤苗 免疫疗法 

分 类 号：R730.51[医药卫生—肿瘤]